Riskpilot← Back to searchSign inGet full accessMundipharma A/S
A/SActiveCVR 17981994Frydenlundsvej 30Wholesale of pharmaceutical and medical goods · NACE 4646Est. 19943 employees
Revenue 2024
DKK 26,4M
-26% vs 2023
EBITDA margin
3.0%
-30% vs 2023
Equity ratio
69.5%
Financial strength
Net profit 2024
DKK 514K
-43% vs 2023
| Revenue | DKK 26,4M | -26% |
| EBITDA | DKK 793K | -30% |
| Net profit | DKK 514K | -43% |
| Total assets | DKK 53,9M | +11% |
| Equity | DKK 37,5M | +1% |
| Employees | 3 | — |
Legal name
Mundipharma A/S
CVR number
17981994
Legal form
Aktieselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
1. august 1994
Share capital
DKK 4.500.000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af ethvert medlem af direktion eller bestyrelse eller af den samlede bestyrelse
Company purpose
Selskabets formål er at drive handel og industri.
Address
Frydenlundsvej 30
Phone
+4547174800
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 51.563 | 48.453 | 40.102 | 35.938 | 26.430 |
| Staff expenses | -29.190 | -8.951 | -5.542 | -1.951 | -2.264 |
| EBITDA | 1.636 | 1.510 | 1.255 | 1.131 | 793 |
| Depreciation & amort. | -93 | -57 | -43 | -45 | -0 |
| EBIT | 1.543 | 1.454 | 1.212 | 1.086 | 793 |
| Net financials | -379 | -284 | -291 | 64 | -115 |
| Profit before tax | 1.164 | 1.169 | 921 | 1.150 | 678 |
| Tax | 256 | 259 | 212 | 253 | 164 |
| Net profit | 908 | 910 | 709 | 897 | 514 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 128.551 | 85.666 | 61.135 | 48.751 | 53.921 |
| Equity | 48.218 | 49.128 | 49.837 | 36.979 | 37.493 |
| Long-term debt | 1.336 | 0 | 0 | 0 | 0 |
| Short-term debt | 78.997 | 36.538 | 11.298 | 11.772 | 16.428 |
| Total debt | 80.333 | 36.538 | 11.298 | 11.772 | 16.428 |
EBITDA margin
3.0%
This company
15.8%
Market median
-81% vs market
20202024
Equity ratio
69.5%
This company
38.2%
Market median
+82% vs market
20202024
Return on equity
1.4%
This company
18.4%
Market median
-92% vs market
20202024
Net profit margin
1.9%
This company
8.1%
Market median
-77% vs market
20202024
Asset turnover
0.49×
This company
1.12×
Market median
-56% vs market
20202024
Debt / equity
0.44×
This company
0.62×
Market median
+29% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LK Management | Management | 2024 |
| Former (10) | ||
HR Chief Executive Officer | Chief Executive Officer | 2023 – 2024 |
JM Chief Executive Officer | Chief Executive Officer | 2021 – 2023 |
ET | Audit | 1994 – 1994 |
SL Chief Executive Officer | Chief Executive Officer | 2021 – 2021 |
KK Chief Executive Officer | Chief Executive Officer | 2018 – 2021 |
KM Management | Management | 1994 – 2011 |
PW Management | Management | 2011 – 2014 |
AW Management | Management | 2014 – 2018 |
PE Management | Management | 1994 – 1994 |
| Audit | 1994 – 2001 | |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2025 | |
| Board of Directors | 2025 | |
| Former (11) | ||
| Chairman | 1994 – 1994 | |
| Board of Directors | 1994 – 1997 | |
| Chairman | 2009 – 2018 | |
| Chairman | 2019 – 2025 | |
| Board of Directors | 2023 – 2024 | |
| Board of Directors | 1994 – 2006 | |
| Board of Directors | 2018 – 2019 | |
| Chairman | 2018 – 2019 | |
| Board of Directors | 2025 – 2025 | |
| Board of Directors | 1994 – 1998 | |
| Board of Directors | 1994 – 1994 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 50–66.65% | 50–66.65% | 2001 | |
| Individual | 25–33.32% | 25–33.32% | 2022 | |
| Individual | 25–33.32% | 25–33.32% | 2022 | |
| Individual | 25–33.32% | 25–33.32% | 2001 | |
| Individual | 25–33.32% | 25–33.32% | 2001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Mundipharma A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hywel Rhys Day | Chief Executive Officer | 0 companies |
| Jennie Maria Synnöve Tjernström | Chief Executive Officer | 0 companies |
| Lisbeth Kattenhøj | Management | 0 companies |
| Erik Tronborg Andersen | Audit | 0 companies |
| Salvador Lopez Orland | Chief Executive Officer | 0 companies |
| Kjetil Kollstad | Chief Executive Officer | 0 companies |
| Kaare Madsen | Management | 0 companies |
| Per Wester | Management | 0 companies |
| Anders With Fogstrup | Management | 0 companies |
| Per Emil Hasselbalch Stakemann | Management | 0 companies |
| PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSAKTIESELSKAB | Audit | 0 companies |
| Ulf Svejgaard Poulsen | Chairman | 0 companies |
| Jesper Knudsen | Board of Directors | 0 companies |
| Christopher Benbow Mitchell | Chairman | 0 companies |
| Jörg Fischer | Chairman | 0 companies |
| Floris Anne Everard Bongenaar | Board of Directors | 0 companies |
| Jens Ole Nielsen | Board of Directors | 0 companies |
| Åke Gunnar Wikström | Board of Directors | 0 companies |
| Stephen Johan Jamieson | Chairman | 0 companies |
| Elliot James Haddock | Board of Directors | 0 companies |
| Stuart David Baker | Chairman | 0 companies |
| Sarah Anna Heidrich | Board of Directors | 0 companies |
| Peter Tærø Nielsen | Board of Directors | 0 companies |
| Hans Christian Galst | Board of Directors | 0 companies |